← All trials
NCT05051332
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 19, 2020
- Primary completion
- Sep 30, 2023
- Completion date
- Sep 30, 2024
- First posted
- Sep 21, 2021
- Last posted
- Sep 29, 2021
- Enrollment
- 104
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Biosolution Co., Ltd.Lead sponsor
- Korea UniversityOverall official - principal investigator
- Kyung Hee UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Chosun UniversityOverall official - principal investigator
- Chungnam National UniversityOverall official - principal investigator
- Ewha Womans UniversityOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- Kosin UniversityOverall official - principal investigator
- Pusan National UniversityOverall official - principal investigator
- Chonnam National UniversityOverall official - principal investigator
- Biosolution Co., Ltd.Study director
- Inje UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.